Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 14/20 | 0.37 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | KDM4A | O75164 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
| ▸ | TGM2 | P21980 | 1/20 | 0.30 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29330934 | 0.86 | CPB2 (0.39) | CPB2FOLH1KISS1RSMN1; SMN2KDM4A | |
| SCHEMBL13057114 | 0.78 | CPB2 (0.43) | CPB2FOLH1KISS1RSMN1; SMN2KDM4A | |
| SCHEMBL19401625 | 0.78 | CPB2 (0.43) | CPB2FOLH1KISS1RSMN1; SMN2KDM4A | |
| SCHEMBL434550 | 0.78 | CPB2 (0.43) | CPB2FOLH1KISS1RSMN1; SMN2KDM4A | |
| SCHEMBL3438650 | 0.77 | CPB2 (0.42) | CPB2FOLH1KISS1RSMN1; SMN2KDM4A | |
| SCHEMBL17087044 | 0.75 | CPB2 (0.41) | CPB2FOLH1KISS1RSMN1; SMN2KDM4A | |
| SCHEMBL22020398 | 0.75 | KISS1R (0.34) | CPB2KISS1RNOD1 | |
| SCHEMBL24410436 | 0.74 | CPB2 (0.40) | CPB2FOLH1KISS1RSMN1; SMN2KDM4A | |
| SCHEMBL13595628 | 0.74 | FOLH1 (0.54) | CPB2FOLH1KISS1RSMN1; SMN2NOD1 | |
| SCHEMBL21673279 | 0.74 | FOLH1 (0.54) | CPB2FOLH1KISS1RSMN1; SMN2NOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140256626-A1 | PEG CONJUGATES OF EXENATIDE | PROLYNX LLC | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256626-A1 | PEG CONJUGATES OF EXENATIDE | GIPR, GHRHR, GLP1R | CPB2 3193/4885FOLH1 297/4885KISS1R 113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.